Illumina Q4 and Fiscal Year 2015 Financial Results

February 2, 2016

© 2015 Illumina, Inc. All rights reserved.

Illumina, 24sure, BaseSpace, BeadArray, BlueFish, BlueFuse, BlueGnome, cBot, CSPro, CytoChip, DesignStudio, Epicentre, ForenSeq, Genetic Energy, GenomeStudio, GoldenGate, HiScan, HiSeq, HiSeq X, Infinium, IScan, iSelect, MiSeq, MiSeqDx, MiSeq FGx, NeoPrep, NextBio, Nextera, NextSeq, Powered by Illumina, SureMDA, TruGenome, TruSeq, TruSight, Understand Your Genome, UYG, VeraCode, verifi, VeriSeq, the pumpkin orange color, and the streaming bases design are trademarks of Illumina, Inc. and/or its affiliate(s) in the US and/or other countries. All other names, logos, and other trademarks are the property of their respective owners.



Safe Harbor Statement

This communication may contain statements that are forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables and to deploy new products, services, and applications, and expand the markets, for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products, or businesses; (iv) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate; (v) challenges inherent in developing, manufacturing, and launching new products and services; and (vi) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

illumina

Q4 2015 Highlights

Revenue growth exceeded expectations

Q4 highlights:

- Revenue growth of 15% YoY
- Constant currency revenue growth of 19% YoY
- Revenue growth driven by strength from benchtop instruments, sequencing consumables and services
- Operating margin decline related to lower gross margin, higher headcount and strategic investments
- Cash flow from operations of \$240 million

	Q4 15	Q4 14	Δ
Revenue ¹	\$592	\$512	15%
Gross Margin ²	71.7%	72.3%	(60 bps)
Operating Margin ²	33.4%	37.7%	(430 bps)
EPS ³	\$0.81	\$0.87	(7%)
	2015	2014	Δ
Revenue ¹	2015 \$2,220	2014 \$1,861	Δ 19%
Revenue ¹ Gross Margin ²			
	\$2,220	\$1,861	19%

3 3. Non-GAAP EPS attributable to Illumina stockholders, including stock based compensation expense

^{1.} In millions

^{2.} Adjusted non-GAAP as a percentage of revenue excluding stock based compensation expense

illumina

Q4 2015 Revenue Growth Rates

Sequencing consumables and services fueled Q4 revenue growth

Q4 YoY %	Sequencing ²	Microarray ²	Total
Instruments	(5%)	N/P ¹	(5%)
Consumables	~30%	(7%)	19%
Service and Other	N/P ¹	N/P ¹	~50%
Total	19%	(2%)	15%

- Consumables accounted for 59% of total revenue
- Sequencing consumables were approximately \$280M
- Microarrays were approximately 15% of total revenue

^{1.} N/P items are not provided

^{2.} Total sequencing and microarray revenue includes consumables, instruments, services, warranty, freight and other

2015 Revenue Growth Rates

Services and sequencing consumables fueled FY'15 revenue growth

2015 YoY %	Sequencing ²	Microarray ²	Total
Instruments	8%	N/P ¹	6%
Consumables	34%	(10%)	23%
Service and Other	N/P ¹	N/P ¹	36%
Total	26%	(10%)	19%

- Consumables accounted for 58% of total revenue
- Sequencing consumables were approximately \$1.03B
- Microarrays were approximately 14% of total revenue

^{1.} N/P items are not provided

^{2.} Total sequencing and microarray revenue includes consumables, instruments, services, warranty, freight and other

Sequencing Power for Every Scale

The broadest portfolio offering available



	MiniSeq	MiSeq	NextSeq	HiSeq		HiSe	eq X	
				2500	4000	X Five	X Ten	
Output per Run:	7.5 Gb	15 Gb	120 Gb	1 Tb	1.5 Tb	1.8 Tb	1.8 Tb	
Instrument Price:	\$49.5K	\$99K	\$250K	\$690K	\$900K	\$6M ¹	\$10M ¹	
\$ Price/Gb:	\$200	\$93	\$33	\$29	\$20	\$10.5	\$7	
Utilization: ²	\$12K–\$15K	\$40K-\$45K	\$100K–\$125K	\$300K-\$350K		\$650K-	-\$700K	
Installed Base: ³	0	>4,300	~1,150	~2,050		~300		

1. Price based on purchase of 5 or 10 units for HiSeq X Five and HiSeq X Ten, respectively

2. Company's projected annual instrument utilization

3. Based on end of fiscal year 2015

Q4 2015 Non-GAAP P&L

\$ in millions, except % and per share data	Q4 15	Q4 14	Δ
Revenue	\$592	\$512	15%
GM % ¹	71.7%	72.3%	(60 bps)
R&D % ¹	17.5%	15.7%	180 bps
SG&A %1	20.9%	18.9%	200 bps
OM %1	33.4%	37.7%	(430 bps)
Stock Based Compensation	\$35	\$38	(8%)
Tax Rate	26.5%	16.2%	1,030 bps
Consolidated Net Income ²	\$119	\$129	(8%)
Add: Net Loss Attributable to Noncontrolling Interests	\$2	-	NA
Net Income Attributable to Illumina Stockholders ³	\$121	\$129	(6%)
EPS ³ Attributable to Illumina Stockholders	\$0.81	\$0.87	(7%)
 Adjusted non-GAAP as a percentage of Non-GAAP including stock based compo Non-GAAP attributable to Illumina stock 	ensation expense		illumina

3. Non-GAAP attributable to Illumina stockholders, including stock based compensation expense

2015 Non-GAAP P&L

\$ in millions, except % and per share data	2015	2014	Δ
Revenue	\$2,220	\$1,861	19%
GM % ¹	72.4%	71.7%	70 bps
R&D % ¹	16.2%	15.3%	90 bps
SG&A %1	19.8%	19.5%	30 bps
OM % ¹	36.4%	36.9%	(50 bps)
Stock Based Compensation	\$133	\$153	(13%)
Tax Rate	27.1%	23.6%	350 bps
Consolidated Net Income ²	\$491	\$407	21%
Add: Net Loss Attributable to Noncontrolling Interests	\$4	-	NA
Net Income Attributable to Illumina Stockholders ³	\$495	\$407	22%
EPS ³ Attributable to Illumina Stockholders	\$3.32	\$2.74	21%
Adjusted non-GAAP as a percentage o Non-GAAP including stock based comp Non-GAAP attributable to Illumina stock	pensation expense		illumına

3. Non-GAAP attributable to Illumina stockholders, including stock based compensation expense

Balance Sheet / Cash Flow

Strong cash generation


\$ in millions, except DSO	Q4 15	Q3 15
Cash & Investments	\$1,386	\$1,439
Inventory	\$271	\$234
Accounts Receivable (DSO)	\$386 (64)	\$413 (68)
Operating Cash Flow	\$240	\$181
Free Cash Flow	\$205	\$152

- ▶ In Q4'15, \$29M of the 2016 0.25% convertible bonds were settled
- Repurchased \$202M of common stock in Q4'15 under share repurchase programs (average price \$151.44)
- Inventory increase due to a buildup of sequencing instruments and safety stock

illumina

2016 Guidance⁵

Continuing to deliver strong revenue growth




1. Revenue guidance assumes constant currency rates from January 29, 2016; a 1% headwind from currency is included in total company revenue guidance

2. Non-GAAP EPS attributable to Illumina stockholders, including stock based compensation expense; Includes \$0.10 and \$0.15 of dilution from Helix and GRAIL, respectively

- 3. Adjusted non-GAAP excluding stock based compensation expense
- 4. Non-controlling interest is the portion of net loss associated with Helix and GRAIL that is not attributable to the Illumina shareholders
- 5. Guidance given by press release and 8-k on February 2, 2016



Non-GAAP Reconciliations





Reconciliation Between GAAP and Non-GAAP Earnings Per Share Attributable to Illumina Stockholders:

		Three Months Ended			Years Ended			
		January 3, 2016		December 28, 2014		January 3, 2016	De	cember 28, 2014
GAAP earnings per share attributable to Illumina								
stockholders - diluted	\$	0.70		\$ 1.03	\$	3.10	\$	2.37
Amortization of acquired intangible assets		0.09		0.08		0.35		0.32
Non-cash interest expense (a)		0.06		0.07		0.26		0.26
Legal contingencies (b)		0.03		(0.40)		0.13		(0.24)
Contingent compensation expense (c)		_		_		_		0.03
Headquarter relocation		_		0.01		(0.02)		0.04
Loss on extinguishment of debt		_		_		0.03		0.21
Acquisition related expense (gain), net (d)		_		(0.02)		(0.04)		(0.02
Cost-method investment gain, net (e)		_		_		(0.10)		(0.03
Tax benefit related to cost-sharing arrangement (f)		_		—		(0.17)		_
Incremental non-GAAP tax (expense) benefit (g)		(0.07)		0.10		(0.22)		(0.20)
Non-GAAP earnings per share attributable to Illumina								
stockholders - diluted (h)	\$	0.81		\$ 0.87	\$	3.32	\$	2.74
Shares used in calculating non-GAAP diluted earnings per	_							
share attributable to Illumina stockholders	_	148,952		148,657	_	149,069		148,815
ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GA							-	-
GAAP net income attributable to Illumina stockholders	\$	104,477		,	\$	461,559	\$	353,351
Amortization of acquired intangible assets Non-cash interest expense (a)		12,376 8,705		12,203		51,829		48,165 38,154
Legal contingencies (b)		4,000		10,099 (59,483)		38,589 19,000		(35,931
Contingent compensation expense (c)		4,000		(59,485)		934		4,265
Headquarter relocation		436		1,281		(2,611)		4,203 5,638
Loss on extinguishment of debt		325		1,201		4,062		31,360
0		325		(2,304)				
Acquisition related expense (gain), net (d)				(2,304)		(6,124)		(2,639
Cost-method investment gain, net (e)		(119)		(405)		(15,601)		(4,427
Impairments (i)		(F.C)		(485)				(485
Tax benefit related to cost-sharing arrangement (f)		(56)		12.025		(24,813)		(20.224
Incremental non-GAAP tax (expense) benefit (g)	_	(10,584)		13,925	-	(31,621)		(30,234
Non-GAAP net income attributable to Illumina	÷	420 570		* 120.040	÷	405 202	~	407 247
stockholders (h)	<u>\$</u>	120,570		\$ 128,949	<u>Ş</u>	495,203	<u>Ş</u>	407,217
ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GA	٩AF	DILUTED NUM	ЛE	BER OF SHARES A	TTI	RIBUTABLE TO I	LLUN	ЛINA
STOCKHOLDERS:								
Weighted average shares used in calculation of GAAP								
diluted earnings per share		148,952		148,657		149,069		148,977
Weighted average dilutive potential common shares								
issuable of redeemable convertible senior notes	_	_	_		_		_	(162
Weighted average shares used in calculation of non-								
GAAP diluted earnings per share attributable to Illumina								
stockholders		148,952		148,657		149,069		148,815
	-			-,	-	- , ,	_	

Reconciliation Between GAAP and Non-GAAP Tax Provision:

		Three Mon	ths Ended	Year Ended						
		January 3, December 28, 2016 2014			January 2016	3,	December 28, 2014			
GAAP tax provision	\$ 32,143	23.8 %	\$ 38,781	20.2 %	\$ 125,752	21.6 %	\$ 95,407	21.3 %		
Incremental tax expense (g)	10,584	39.6 %	(13,925)	36.4 %	31,621	35.1 %	30,234	36.0 %		
Tax benefit related to cost-sharing										
arrangement(f)	56	—		—	24,813	_		—		
Non-GAAP tax provision	\$ 42,783	26.5 %	\$ 24,856	16.2 %	\$ 182,186	27.1 %	\$ 125,641	23.6 %		

Footnotes to the Reconciliation Between GAAP and Non-GAAP Measures:

(a) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(b) Legal contingencies in fiscal 2015 represent charges related to patent litigation. Legal contingencies in fiscal 2014 primarily represent a gain related to the settlement of our patent litigation with Syntrix Biosystems, Inc., partially offset by the expenses recorded upon our litigation settlement and pooling of patents with Sequenom, Inc.

(c) Contingent compensation expense relates to contingent payments for post-combination services associated with an acquisition.

(d) Acquisition related expense (gain), net consists of changes in fair value of contingent consideration and transaction related costs.

(e) Cost-method investment gain, net consists primarily of gains on disposition of investments partially offset by impairment charges on other investments.

(f) Tax benefit related to cost-sharing arrangement refers to the exclusion of stock compensation from prior period cost-sharing charges as a result of a recent tax court ruling.

(g) Incremental non-GAAP tax (expense) benefit reflects the tax impact related to the non-GAAP adjustments listed above.

(h) Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders exclude the effect of the pro forma adjustments as detailed above. Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key drivers of the Company's core operating performance and major factors in management's bonus compensation each year. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance.

(i) Impairments in fiscal 2014 consisted of a gain on an asset sale associated with a non-core product line discontinued in 2013, partially offset by an intangible asset impairment.



Reconciliation Between GAAP and Non-GAAP Results of Operations as a Percent of Revenue:

	_	-	Three Mor	nth	s Ended		Years Ended					
		Januar 201			Decemb 201			January 3, 2016			Decembe 2014	
GAAP gross profit	Ś	410,359	-	Ś	384,937		Ś	1,549,290		Ś	1,297,710	69.7 %
Stock-based compensation	Ŧ	,			,		Ŧ	_,,		T	_,,	
expense		3,195	0.5 %		2,959	0.6 %		11,450	0.5 %		10,655	0.6 %
Amortization of acquired		-,			,			,			-,	
intangible assets		10,853	1.8 %		10,616	2.1 %		45,810	2.1 %		39,373	2.1 %
Legal contingencies (a)		_	_		(26,240)	(5.1)%		_	_		(10,393)	(0.6)9
Impairments (b)		_	_		(2,000)	(0.4)%		_	_		(2,000)	(0.1)9
Non-GAAP gross profit (c)	\$	424,407	71.7 %	\$	370,272	72.3 %	\$	1,606,550	72.4 %	\$	1,335,345	71.7 9
GAAP research and development												
expense		114,347	19.3 %	Ś	142,947	27.9 %	Ś	401,527	18.1 %	Ś	388,055	20.8 9
Stock-based compensation	Ŧ	,e .,		Ŧ	,		Ť	,	//	Ŧ		
expense		(10,849)	(1.8)%		(11,837)	(2.3)%		(42,001)	(1.9)%		(50,880)	(2.7)
Contingent compensation expense	2	(10,043)	(1.0)/0		(11,057)	(2.3)/0		(42,001)	(1.5)/0		(30,000)	(2.7)
(d)	-	(83)	_		(433)	(0.1)%		(127)	_		(1,509)	(0.1)
Legal contingencies (a)		(05)	_		(48,800)	(9.5)%		(127)	_		(48,800)	(2.6)
Impairments (b)		_	_		(1,515)	(0.3)%		_	_		(1,515)	(0.1)
Non-GAAP research and	_			-	(1,515)	(0.37/0	-			_	(1,515)	(0.1)
development expense	\$	103,415	17.5 %	\$	80,362	15.7 %	\$	359,399	16.2 %	ċ	285,351	15.3 9
development expense	<u>></u>	105,415		<u>2</u>	80,302	/	<u>2</u>		10.2 /0	<u>γ</u>	203,331	
GAAP selling, general and												
administrative expense	\$	147,251	24.9 %	\$	122,173	23.8 %	\$	524,657	23.6 %	\$	466,283	25.1 9
Stock-based compensation		,						-		-	-	
expense		(21,445)	(3.6)%		(23,666)	(4.6)%		(79,142)	(3.5)%		(91,016)	(4.9)
Amortization of acquired		() - /	(/)		(-//	(- <i>I</i> -		(-) /	(<i>j</i> ·		(- //	(- <i>j</i> -
intangible assets		(1,523)	(0.3)%		(1,587)	(0.3)%		(6,019)	(0.3)%		(8,792)	(0.6)9
Contingent compensation expense	2	())	()-		())	()		(-))	()		(-/ - /	()
(d)		(602)	(0.1)%		_	_		(807)	_		(2,756)	(0.1)
Non-GAAP selling, general and	_	(002)						(001)			(_); ; ; ; ; ;	
administrative expense	<u>\$</u>	123,681	20.9 %	<u>\$</u>	96,920	18.9 %	\$	438,689	19.8 %	<u>\$</u>	363,719	19.5 9
GAAP operating profit	Ś	144,000	24.3 %	¢	202,883	39.6 %	¢	612,841	27.6 %	Ś	514,711	27.7 9
Stock-based compensation	Ŷ	144,000	24.3 /0	Ŷ	202,003	33.0 /0	Ŷ	012,041	27.0 /0	Ŷ	514,711	27.7 /
expense		35,489	6.0 %		38,462	7.5 %		132,593	5.9 %		152,551	8.2 %
Amortization of acquired		55,405	0.0 /0		30,402	7.5 70		152,555	5.5 70		152,551	0.2 /
intangible assets		12,376	2.1 %		12,203	2.4 %		51,829	2.4 %		48,165	2.6 %
Legal contingencies (a)		4,000	0.7 %		(59,483)	(11.6)%		19,000	0.9 %		(35,931)	(1.9)
Contingent compensation expense	`	4,000	0.7 /0		(39,463)	(11.0)/0		19,000	0.9 /0		(33,931)	(1.9)
(d)	-	685	0.1 %		433	0.1 %		934	_		4,265	0.2 9
			0.1 %						(0,1)%			
Headquarter relocation		436	0.1 %		1,281	0.2 %		(2,611)	(0.1)%		5,638	0.2 %
Acquisition related expense (gain),	,	225	0 1 0/		(2 204)	(0,4)0/		(6 124)	(0.2.)0/		(2, (20))	(0.1)0
net (e)		325	0.1 %		(2,304)	(0.4)%		(6,124)	(0.3)%		(2,639)	(0.1)%
Impairments (b)	<u>_</u>			-	(485)	(0.1)%	~			~	(485)	
Non-GAAP operating profit (c)	<u>\$</u>	197,311	33.4 %	<u>\$</u>	192,990	37.7 %	<u>\$</u>	808,462	36.4 %	<u>\$</u>	686,275	36.9 %
GAAP other expense, net	\$	(8,993)	(1.5)%	\$	(10,822)	(2.1)%	\$	(29,699)	(1.3)%	\$	(65,953)	(3.5)%
Non-cash interest expense (f)		8,705	1.5 %		10,099	2.0 %		38,589	1.7 %	-	38,154	2.0 9
Loss on extinguishment of debt		325						4,062	0.2 %		31,360	1.7 9
Cost-method investment gain, net		525						.,002	012 /0		01,000	1., ,
(g)		(119)	_		_	_		(15,601)	(0.7)%		(4,427)	(0.2)
				-								/
Non-GAAP other expense, net (c)	Ş	(82)	_	\$	(723)	(0.1)%	Ş	(2,649)	(0.1)%	Ş	(866)	—

Footnotes to the Reconciliation Between GAAP and Non-GAAP Results of Operations:

(a) Legal contingencies in fiscal 2015 represent charges related to patent litigation. Legal contingencies recorded in fiscal 2014 primarily represent a gain related to the settlement of our patent litigation with Syntrix Biosystems, Inc., or Syntrix, partially offset by the expenses recorded upon our litigation settlement and pooling of patents with Sequenom, Inc., or Sequenom. The gain associated with the Syntrix settlement was recorded partially as a reversal of cost of sales and partially as a reduction of operating expense. The upfront payments to Sequenom were recorded in research and development expense.

(b) Impairments in fiscal 2014 consisted of a gain recorded in cost of sales on an asset sale associated with a non-core product line discontinued in 2013, partially offset by an intangible asset impairment recorded in research and development expense.

(c) Non-GAAP gross profit, included within non-GAAP operating profit, is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of the Company's products and services. Non-GAAP operating profit, and non-GAAP other expense, net, exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future core operating performance.

(d) Contingent compensation expense relates to contingent payments for post-combination services associated with an acquisition.

(e) Acquisition related expense (gain), net consists of changes in fair value of contingent consideration and transaction related costs.

(f) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(g) Cost-method investment gain, net consists primarily of gains on disposition of investments partially offset by impairment charges on other investments.

illumina

Reconciliation of Non-GAAP Financial Guidance

	Fiscal Year 2016
Gross margin	
Non-GAAP gross margin	73%
Amortization of acquired intangible assets	(2)%
GAAP gross margin	71%
Operating margin	
Non-GAAP operating margin (a)	33%
Stock-based compensation expense	(6)%
Amortization of acquired intangible assets	(2)%
GAAP operating margin	25%
Diluted earnings per share attributable to Illumina stockholders	
Non-GAAP diluted earnings per share attributable to Illumina stockholders	\$3.55 - \$3.65
Amortization of acquired intangible assets	(0.32)
Non-cash interest expense (b)	(0.20)
Contingent compensation (c)	(0.02)
Headquarter relocation (d)	(0.01)
Incremental non-GAAP tax expense (e)	0.19
GAAP diluted earnings per share attributable to Illumina stockholders	\$3.19 - \$3.29

(a) Operating margin implied at the mid-point of guidance provided for non-GAAP diluted earnings per share.

(b) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.

(c) Contingent compensation expense relates to contingent payments for post-combination services associated with an acquisition.

(d) Headquarter relocation represents accretion of interest expense on lease exit liability and changes in estimate of such liability.

(e) Incremental non-GAAP tax expense reflects the tax impact related to the non-GAAP adjustments listed above.